Atorvastatin inhibits GSK-3β phosphorylation by cardiac hypertrophic stimuli

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1781, Issue 1-2, 2008, Pages 26-35

  Planavila, Anna ^a   Rodríguez Calvo, Ricardo ^a   Palomer, Xavier ^a   Coll, Teresa ^a   Sánchez, Rosa M ^a   Merlos, Manuel ^a   Laguna, Juan C ^a   Vázquez Carrera, Manuel ^a  

^a Pharmacology Unit   (Spain)

Author keywords

Atorvastatin; Cardiac hypertrophy; GSK 3 ; PTEN

Indexed keywords

ATORVASTATIN; GLYCOGEN SYNTHASE KINASE 3; PROTEIN C JUN; PROTEIN KINASE B; TRANSCRIPTION FACTOR GATA 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; GEL MOBILITY SHIFT ASSAY; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; ENZYME ACTIVATION; GATA4 TRANSCRIPTION FACTOR; GLYCOGEN SYNTHASE KINASE 3; HEPTANOIC ACIDS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 39149096851     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2007.10.009     Document Type: Article

References (46)

1. Sugden P.H. Signaling in myocardial hypertrophy - life after calcineurin?. Circ. Res. 84 (1999) 633
2. Olson E.N., and Molkentin J.D. Prevention of cardiac hypertrophy by calcineurin inhibition - hope or hype?. Circ. Res. 84 (1999) 623
3. Hunter J.J., and Chien K.R. Mechanisms of disease - signaling pathways for cardiac hypertrophy and failure. N. Engl. J. Med. 341 (1999) 1276
4. Sadoshima J., and Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu. Rev. Physiol. 59 (1997) 551
5. Morisco C., Zebrowski D., Condorelli G., Tsichlis P., Vatner S.F., and Sadoshima J. The Akt-glycogen synthase kinase 3 beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes. J. Biol. Chem. 275 (2000) 14466
6. Haq S., Choukroun G., Kang Z.B., Ranu H., Matsui T., Rosenzweig A., Molkentin J.D., Alessandrini A., Woodgett J., Hajjar R., Michael A., and Force T. Glycogen synthase kinase-3 beta is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 151 (2000) 117
7. Badorff C., Ruetten H., Mueller S., Stahmer M., Gehring D., Jung F., Ihling C., Zeiher A.M., and Dimmeler S. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J. Clin. Invest. 109 (2002) 373
8. Dorn G.W., and Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J. Clin. Invest. 115 (2005) 527
9. Crackower M.A., Oudit G.Y., Kozieradzki I., Sarao R., Sun H., Sasaki T., Hirsch E., Suzuki A., Shioi T., Irie-Sasaki J., Sah R., Cheng H.Y.M., Rybin V.O., Lembo G., Fratta L., Oliveira-dos-Santos A.J., Benovic J.L., Kahn C.R., Izumo S., Steinberg S.F., Wymann M.P., Backx P.H., and Penninger J.M. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110 (2002) 737
10. Schwartzbauer G., and Robbins J. The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J. Biol. Chem. 276 (2001) 35786
11. Leslie N.R., Bennett D., Lindsay Y.E., Stewart H., Gray A., and Downes C.P. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 22 (2003) 5501
12. Morisco C., Seta K., Hardt S.E., Lee Y., Vatner S.F., and Sadoshima J. Glycogen synthase kinase 3 beta regulates GATA4 in cardiac myocytes. J. Biol. Chem. 276 (2001) 28586
13. Boyle W.J., Smeal T., Defize L.H.K., Angel P., Woodgett J.R., Karin M., and Hunter T. Activation of protein-kinase-C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 64 (1991) 573
14. Nikolakaki E., Coffer P.J., Hemelsoet R., Woodgett J.R., and Defize L.H.K. Glycogen-synthase kinase-3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact-cells. Oncogene 8 (1993) 833
15. vonHarsdorf R., Edwards J.G., Shen Y.T., Kudej R.K., Dietz R., Leinwand L.A., NadalGinard B., and Vatner S.F. Identification of a cis-acting regulatory element conferring inducibility of the atrial natriuretic factor gene in acute pressure overload. J. Clin. Invest. 100 (1997) 1294
16. Takemoto M., Node K., Nakagami H., Liao Y.L., Grimm M., Takemoto Y., Kitakaze M., and Liao J.K. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108 (2001) 1429
17. Senthil V., Chen S.N., Tsybouleva N., Halder T., Nagueh S.F., Willerson J.T., Roberts R., and Marian A.J. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ. Res. 97 (2005) 285
18. Cabrero A., Alegret M., Sanchez R.M., Adzet T., Laguna J.C., and Vazquez M. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes 50 (2001) 1883
19. Kimura Y., Otsu K., Nishida K., Kuzuya T., and Tada M. Thyroid-hormone enhances Ca2+ pumping activity of the cardiac sarcoplasmic-reticulum by increasing Ca2+ ATPase and decreasing phospholamban expression. J. Mol. Cell. Cardiol. 26 (1994) 1145
20. Davidson M.M., Nesti C., Palenzuela L., Walker W.F., Hernandez E., Protas L., Hirano M., and Isaac N.D. Novel cell lines derived from adult human ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 39 (2005) 133
21. Cabrero A., Alegret M., Sanchez R.M., Adzet T., Laguna J.C., and Carrera M.V. Increased reactive oxygen species production down-regulates peroxisome proliferator-activated alpha pathway in C2C12 skeletal muscle cells. J. Biol. Chem. 277 (2002) 10100
22. Arai H., Nakao K., Saito Y., Morii N., Sugawara A., Yamada T., Itoh H., Shiono S., Mukoyama M., Ohkubo H., Nakanishi S., and Imura H. Augmented expression of atrial natriuretic polypeptide gene in ventricles of spontaneously hypertensive rats (Shr) and Shr-stroke prone. Circ. Res. 62 (1988) 926
23. Edwards B.S., Ackermann D.M., Lee M.E., Reeder G.S., Wold L.E., and Burnett J.C. Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart-failure. J. Clin. Invest. 81 (1988) 82
24. Drexler H., Hanze J., Finckh M., Lu W., Just H., and Lang R.E. Atrial natriuretic peptide in a rat model of cardiac-failure - atrial and ventricular messenger-RNA, atrial content, plasma-levels, and effect of volume loading. Circulation 79 (1989) 620
25. Laufs U., Kilter H., Konkol C., Wassmann S., Bohm M., and Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovas. Res. 53 (2002) 911
26. Pikkarainen S., Tokola H., Majalahti-Palviainen T., Kerkela R., Hautala N., Bhalla S.S., Charron F., Nemer M., Vuolteenaho O., and Ruskoaho H. GATA-4 is a nuclear mediator of mechanical stretch-activated hypertrophic program. J. Biol. Chem. 278 (2003) 23807
27. Herzig T.C., Jobe S.M., Aoki H., Molkentin J.D., Cowley A.W., Izumo S., and Markham B.E. Angiotensin II type(1a) receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 7543
28. Meng F.Y., Liu L., Chin P.C., and D'Mello S.R. Akt is a downstream target of NF-kappa B. Journal of Biological Chemistry 277 (2002) 29674
29. Higuchi Y., Otsu K., Nishida K., Hirotani S., Nakayama H., Yamaguchi O., Matsumura Y., Ueno H., Tada M., and Hori M. Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J. Mol. Cell. Cardiol. 34 (2002) 233
30. Nakamura K., Fushimi K., Kouchi H., Mihara K., Miyazaki M., Ohe T., and Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-a and angiotensin II. Circulation 98 (1998) 794
31. Schulz R. Pleiotropic effects of statins: acutely good, but chronically bad?. J. Am. Coll. Cardiol. 45 (2005) 1292
32. Seo J.H., Ahn Y., Lee S.R., Yeol Y.C., and Chung H.K. The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phosphoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway. Mol. Biol. Cell 16 (2005) 348
33. Lee S.R., Yang K.S., Kwon J., Lee C., Jeong W., and Rhee S.G. Reversible inactivation of the tumor suppressor PTEN by H2O2. J. Biol. Chem. 277 (2002) 20336
34. Hirotani S., Otsu K., Nishida K., Higuchi Y., Morita T., Nakayama H., Yamaguchi O., Mano T., Matsumura Y., Ueno H., Tada M., and Hori M. Involvement of nuclear factor-kappa B and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105 (2002) 509
35. Cook S.A., Matsui T., Li L., and Rosenzweig A. Transcriptional effects of chronic Akt activation in the heart. J. Biol. Chem. 277 (2002) 22528
36. Shioi T., McMullen J.R., Kang P.M., Douglas P.S., Obata T., Franke T.F., Cantley L.C., and Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22 (2002) 2799
37. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., Richardson J.A., Hill J.A., and Olson E.N. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 907
38. Haq S., Choukroun G., Kang Z.B., Ranu H., Matsui T., Rosenzweig A., Molkentin J.D., Alessandrini A., Woodgett J., Hajjar R., Michael A., and Force T. Glycogen synthase kinase-3 beta is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 151 (2000) 117
39. Mensah K., Mocanu M.M., and Yellon D.M. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?. J. Am. Coll. Cardiol. 45 (2005) 1287
40. Lee K.S., Park S.J., Hwang P.H., Yi H.K., Song C.H., Chai O.H., Kim J.S., Lee M.K., and Lee Y.C. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB J. 19 (2005) 1033
41. Lee S.Y., Hur G.Y., Jung K.H., Jung H.C., Lee S.Y., Kim J.H., Shin C., Shim J.J., In K.H., Kang K.H., and Yoo S.H. PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 51 (2006) 297
42. Patel L., Pass I., Coxon P., Downes C.P., Smith S.A., and Macphee C.H. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr. Biol. 11 (2001) 764
43. Zelvyte I., Dominaitiene R., Crisby M., and Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol. Res. 45 (2002) 147
44. Ludwig A., Friedel B., Metzkow S., Meiners S., Stangl V., Baumann G., and Stangl K. Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. Biochem. Pharmacol. 70 (2005) 520
45. Planavila A., Laguna J.C., and Vazquez-Carrera M. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim. Biophys. Acta 1687 (2005) 76
46. Gustin J.A., Maehama T., Dixon J.E., and Donner D.B. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity. J Biol. Chem. 276 (2001) 27740